DISC MEDICINE INC. -

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

04 Nov 2024 06:50:00 By Nasdaq GlobeNewswire

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

01 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

25 Oct 2024 12:00:00 By Nasdaq GlobeNewswire

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

11 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

19 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Disc Medicine Announces Underwritten Offering of Common Stock

14 Jun 2024 07:03:53 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

14 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

14 May 2024 09:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire